New hope for advanced breast cancer: A166 takes on T-DM1 in phase 3 showdown
NCT ID NCT06968585
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This phase 3 trial compares a new drug called A166 to the standard treatment T-DM1 in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Participants must have already tried trastuzumab and a taxane chemotherapy. The main goal is to see if A166 helps people live longer without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.